Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Eli Lilly & Co (LLY – Research Report).

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

U.S. stock futures are edging mostly higher as market participants focus on tech stocks and corporate earnings; Honeywell ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...